Overview

• The offer was subscribed 10.6 times by noon on Day Three, including QIB 2.25x, NII 25.1x, retail 13.85x and employee 7.66x.
• The price band is Rs 461–485 for a Rs 1,377.5 crore issue comprising a Rs 500 crore fresh issue and a Rs 877.5 crore offer for sale, with a retail lot of 30 shares (Rs 14,550 at the upper band).
• An unofficial grey-market premium hovered around Rs 95–96, indicating a possible listing near Rs 581 at the top of the band, according to InvestorGain.
• The company raised Rs 619 crore from anchor investors ahead of the subscription opening.
• Proceeds are earmarked to reduce debt and fund inorganic growth, as the pharma firm reports FY25 PAT of Rs 134.36 crore on income of Rs 1,296.22 crore and operates three Indian plants with US FDA-approved products.